tes—2017: Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(suppl 1):S64-S74. 4.Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and AmericanCollege of Endocrinology on the comprehensive type 2 diabetes man-agement algorithm —2017 executive summary. Endocr Pract . 2017;23: 207-238. 5.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hypergly- cemia in type 2 diabetes, 2015: a patient-centered approach: updateto a position statement of the American Diabetes Association and theEuropean Association for the Study of Diabetes. Diabetes Care . 2015; 38:140-149. 6.Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized,controlled trial. Ann Intern Med . 2011;154:103-112. 7.Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to